Posted by Michael Wonder on 19 Dec 2016
Boehringer Ingelheim and Lilly welcome new recommendation for Jardiance (empagliflozin) tablets in updated American Diabetes Association's 2017 standards
16 December 2016 - Guidelines include new recommendation to consider the use of Jardiance in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death
The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider the use of Jardiance (empagliflozin) tablets in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death. The updated recommendations, which were published in Diabetes Care, reinforce the critical connection between type 2 diabetes and the increased risk of death due to cardiovascular disease.
Jardiance is the first and only type 2 diabetes treatment approved by the U.S. FDA to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease and is the only oral type 2 diabetes medicine shown in a clinical trial to provide this life-saving cardiovascular benefit.
